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ABSTRACT
Since the discovery of the molecular basis of disease, numerous studies have 
reported a correlation between the activity of specific protein receptors and the 
progression of disease. As a result, drug development has become dependent on the 
study of protein receptor activities. The relative inexpense of computing hardware has 
made computational methods an important supplementary tool for receptor modeling. 
This work details an open source software tool that is capable of both efficiently 
screening large peptide mutant libraries and enabling 3-D conformer-based searches 
over local molecular databases.
A Computational Approach to Efficient Peptide Influenced Drug Repurposing
(CAEPIDR) has been developed to explore the conformational ligand binding space
of the α3β2 nicotinic acetylcholine receptor (nAChR) isoform using a library of α-
conotoxin (α-CTx) MII peptide mutants. The screen’s top hits were used to identify
small molecule drugs that might also bind to the receptor. The conformational ligand
binding space of the nAChR was heuristically explored using a genetic algorithm,
which managed a structure-based virtual screen of a 640,000 α-CTx MII peptide
mutant library. A utility was developed to search the PubChem Compound database
for small molecule drugs with a 3-D shape similar to the highest affinity peptides
from the virtual screen.
CAEPIDR’s genetic algorithm-based procedure was able to find 10 peptides with
estimated free energies of binding (with the α3β2-nAChR) below -20 kcal/mol, which
v
can be compared to α-CTx MII’s -12.38 kcal/mol. These peptides were identified
in spite of the genetic algorithm performing docking calculations for only 9,344 of
the 640,000 α-CTx MII mutants. The PubChem Compound search yielded 2 small
molecule drugs with estimated binding energies below -20 kcal/mol.
CAEPIDR has been integrated with DockoMatic to create DockoMatic 2.1, which
can be used to create virtual peptide mutant libraries, virtually dock ligands to
macromolecular receptors, and identify small molecule drugs for disease treatment.
vi
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1CHAPTER 1
INTRODUCTION
1.1 Background
1.1.1 Drug Repurposing
The discovery of the molecular basis of disease has resulted in massive efforts to
research and develop new medicines. So far, de novo drug development has followed
the general pattern: lead candidate identification, prototype development, pre-clinical
testing of the model systems, clinical trials, Food and Drug Administration (FDA)
approval, clinical deployment, and continued monitoring of efficacy and any side
effects associated with long-term use. This process, which has historically yielded
a marketable drug for every 10 candidates that make it to clinical trials, has an
average cost of ≈ $1.2 billion per marketable drug and an average turn around time
of 14 years [1, 2]. Reducing these costs is difficult since the majority of the expenses
are a result of the clinical trials and cannot be circumvented due to federal safety
regulations.
In an effort to reduce development costs, the National Institute of Health (NIH),
universities, and pharmaceutical companies have made use of an alternative strategy
for drug development: drug repurposing. As the name implies, drug repurposing fo-
cuses on the reuse of drugs or small molecules that have already undergone some level
2of clinical testing. Repurposing allows researchers to build upon previous research
and development efforts to expedite and reduce the costs of clinical trials, speeding
the drug’s review by the FDA and, if approved, integration into health care.
Drug repurposing is either receptor or ligand focused. Receptor-oriented repur-
posing is an attempt to identify drugs that can be reused to target another receptor
or family of receptors (e.g., acetylcholine receptors). Drug databases are searched for
small molecules that exhibit a set of characteristics (e.g., structural similarity to a
known ligand or to a receptor’s binding cavity) that makes them likely candidates
for binding to the targeted receptor. Many chemical databases have been created to
support this type of repurposing.
In contrast, ligand-oriented repurposing focuses on finding a new use for a specific
drug. It is a popular approach for pharmaceutical companies since it has the potential
to yield a new pharmaceutical without the majority of the expenses associated with
drug development. Ligand-oriented repurposing is better known to the general public
because of the success of repurposed drugs such as Viagra, Requip, and Colesevelam.
The drug repurposing paradigm has had immense success in recent years, ac-
counting for nearly 30% of the newly (FDA) approved drugs between 1999 and
2008 [3]. This success has been fueled in part by resources, mostly in the form of
large chemical databases, that have been made publicly available by both public
and private institutions. NIH’s PubChem database [4] is a notable example as it
contains structural and bioactivity information for over 51 million small molecules.
It also includes web-based tools for performing substructure, shape, and many other
searches over any of their databases.
31.1.2 Molecular Docking
Ligand-gated ion channels are a class of membrane-bound receptor proteins that are
often involved in cell signalling. These channels are activated or inhibited by ligands:
the peptides and other small molecules that bind to the gate to form a complex
with the receptor. The specialized role played by these receptors in the regulation
of cellular activity has made them a central focus in the fields of biochemistry and
pharmacology, where the goal is often to develop small molecule ligands to activate
or inhibit biologically relevant receptors.
Many diseases have been correlated with abnormalities in specific cellular activ-
ities. For this reason, drug development is largely a search for small molecules that
can activate or inhibit the receptor associated with the abnormal activity. As such,
predicting the interaction of a small molecule and biological receptor is a central
problem in biochemistry and pharmacology. While fast mathematical methods exist
for predicting the interaction strength between two bound molecules of a given orien-
tation, accurately predicting the binding orientation of the two molecules (molecular
docking) is a complex procedure.
There are two common approaches to molecular docking: simulation and comple-
mentary surface modelling. In the complementary surface approach, both the surface
area of the receptor’s complex and the surface area of the ligand are represented as
a set of descriptors, which are then compared to predict the binding orientation of
the ligand. This assessment is relatively fast but limited in its ability to account
for molecular flexibility. Complementary surface modelling lends itself to functional
group-based comparisons, where the ligand’s functional groups can serve as its de-
scriptors for the model.
4In comparison to the surface modelling approach, simulation is more accurate but
has greater computational complexity. In simulations, molecular dynamics techniques
are used in tandem with heuristic search methods to explore the orientation binding
space for a ligand/receptor pair. All pairwise atomic interactions between the two
molecules must be taken into account, subject to the additional degrees of freedom
introduced by ligand and receptor flexibility. These degrees of freedom produce a
huge orientation space, and simulation techniques often use a search heuristic, grid
system, and scoring function to identify low energy1 orientations.
Within the context of this thesis, the term molecular docking (or just docking)
refers to the use of a simulation technique to determine a ligand/receptor pair’s
binding orientation and the application of a scoring function to assess the pair’s
binding affinity.
AutoDock
While molecular docking programs abound, AutoDock [5, 6] is the most popular
amongst researchers and was cited in 2006 almost as often as the 4 next most cited
docking programs combined [7]. AutoDock is a suite of automated docking tools that
simplify the task of molecular docking. It consists of two main programs: autogrid for
calculating coordinate grids to model the target receptor and autodock for simulating
molecular docking within those grids. AutoDock is currently maintained by the
Scripps Research Institute and is free under the GNU General Public License.
AutoDock uses a Lamarckian Genetic Algorithm to search for a ligand/receptor
pair’s lowest energy pose. A genetic algorithm (GA) performs an indeterministic
search, so multiple GA runs will produce different affinity scores for the same lig-
1According to the Gibbs energy function
5and/receptor pair. As such, researchers who use AutoDock will typically use multiple
(100 is standard) GA simulations with different random seeds to more accurately as-
sess a ligand’s binding affinity. Since each simulation results in a predicted orientation
(pose), groups of AutoDock simulations are also termed pose evaluations.
1.1.3 High Throughput Virtual Screening
Drug development typically involves screening large collections of compounds to
identify a small set of compounds that can serve as the starting point for structure
optimization and refinement. In high throughput screening (HTS), machine automa-
tion is leveraged to rapidly estimate the biochemical activity of large collections of
drug-like molecules. A collection of assay plates, containing enclosed wells for storing
and isolating chemical entities, is built and filled with a reactant/reagent pair. After
allowing time for the reaction to occur, humans or machine optical devices measure
and record the extent of the reaction. The expense of this procedure has made
computational methods an important supplementary tool for drug development.
High Throughput Virtual Screening (HTVS) techniques may be categorized as
either ligand-based or structure-based depending on the screening criteria. Ligand-
based techniques are used to identify molecules that are similar to a set of ligands.
The throughput of ligand-based methods is dependent on the similarity metric, but it
is typically on the scale of thousands of chemicals per second. In contrast, structure-
based HTVS techniques use molecular docking methods to identify molecules that
have a high affinity for the target receptor. Structure-based HTVS techniques are
consequently several orders of magnitude slower than their ligand-based counterparts,
and a structure-based HTVS usually requires a parallel computing infrastructure to
achieve an acceptable throughput. Working with parallel computing infrastructures
6can require a large learning curve; fortunately, software programs such as WinDock [8],
BDT [9], Glide [10], and DockoMatic [11, 12] have been built to facilitate HTVS and
make HTVS tools more accessible to researchers who lack computer programming
skills.
1.1.4 DockoMatic 2.0
DockoMatic 2.0 is open source software intended for use by researchers and educa-
tors. It consists of an intuitive graphical interface and a Perl script that uses the
scripts from the AutoDockTools package to set up and run batches of docking jobs
with AutoDock. In addition to single ligand/receptor docking, DockoMatic enables
secondary ligand binding and structure-based HTVS. Ligands and receptors are input
as protein database (pdb) files and the experimentally determined or predicted ligand
binding domain on the receptor is specified with a grid coordinates file (gpf). Dock-
oMatic is capable of submitting and subsequently monitoring hundreds of thousands
of AutoDock jobs.
DockoMatic has the ability to generate a peptide’s structure from an amino acid
sequence and using the Obconformer program (part of the Open Babel tool suite [13])
for the structure’s energy optimization. Dockomatic 2.0 includes the Treepack [14, 15]
program, allowing in silico site-directed mutagenesis for complex peptide and protein
structures using experimentally determined tertiary structure. As a result, a library of
mutated peptides can be screened without manually generating the peptide’s mutated
structure; Treepack handles that on the fly. This greatly reduces the work associated
with screening large collections of peptide mutants, an attribute of DockoMatic that
has been leveraged in this thesis.
71.2 Towards a Drug for Parkinson’s Disease
Epidemiological studies have demonstrated an inverse relationship between the de-
velopment of neurodegenerative disorders and smoking [16, 17, 18], decreased levels
of nicotinic receptors in postmortem studies of person’s who had been aﬄicted with
forms of dementia [19], and nicotine’s ability to improve cognitive function in animals
(including humans) [20]. These results have led many researchers to hypothesize that
nicotinic receptors serve an important role in both neuronal survival and cognitive
function [21]. This hypothesis has made nicotinic acetylcholine receptors (nAChRs),
which are the primary targets for nicotine in the brain, a central focus for researchers
interested in studying neurodegenerative disorders such as Parkinson’s disease.
In addition to nicotine, α-conotoxins have been extensively studied as ligands
for nAChRs. Conotoxins are one of a group of neurotoxin peptides that have been
isolated from the venom of the marine cone snails of genus Conus. They are small
peptides, consisting of 10-30 amino acid residues, and usually contain one or more
disulfide bonds. α-conotoxins have received a lot of attention because, unlike nicotine,
they have been found to selectively block specific nAChR subtypes. This has made
them an important tool for probing the structure-function relationships of nAChRs.
1.2.1 Previous Work
Dr. Owen McDougal and his research team have been investigating α-CTx MII,
a 16 amino acid peptide that exhibits an IC50 of 0.5 nM for the nAChR α3β2-
isoform [22]. α-CTx MII has a primary sequence of GCCSNPVCHLEHSNLC, con-
tains two disulfide bonds between C2-C8 and C3-C16, and features an α-helix initiated
at P6 and ending at S13 (see Figure 1.1). Site-directed mutagenesis studies on
8nAChRs, investigations into the alteration of the primary sequence of α-CTx MII, and
molecular modeling approaches have all been conducted to understand the selectivity
and potency of α-CTx MII and its variants [23, 24, 25]. Notably, the results of a
study by Bordia and colleagues showed the E11A mutant of the α-CTx MII peptide
demonstrated a 50-fold binding preference for the α6α4β2β3-nAChR isoform [26].
Figure 1.1: Primary sequence for α-CTx MII with disulfide linkages.
The findings of these studies motivated the team to develop a drug repurposing
workflow that could be used to identify strong candidates for pharmaceuticals to treat
Parkinson’s disease. The workflow was:
Peptide Mutant Screening Perform a structure-based HTVS of an α-CTx MII
mutant library to find peptides with high binding affinity for the α3β2-nAChR.
Search PubChem Compound Use these peptide structures to perform a ligand-
based HTVS of the PubChem Compound database and identify FDA approved
drugs with 3-D conformers similar to the high affinity peptides.
Verification Screening Perform molecular docking calculations between the result-
ing small molecule drugs and the α3β2-nAChR.
Synthesize Purchase or synthesize the highest affinity small molecules.
9Wet Lab Use lab-based experiments, such as the two electrode voltage clamp ex-
periment, to confirm that the predicted binding affinity translates to biological
activity.
Extension Use the developed workflow to study the more biologically relevant nAChR
α6α4β2β3-isoform in order to develop a drug to treat Parkinson’s disease.
As the first step in the workflow, the team decided to perform an in silico com-
binatorial chemistry experiment-based on the α-CTx MII peptide. They constructed
a library of α-CTx MII mutants and wanted to use structure-based HTVS methods
to identify peptides with a high binding affinity to the α3β2-nAChR. A pentameric
homology model of the α3β2 isoform of rat neuronal nAChR [27] was used for the
initial experiment since it was the best available expression of a nAChR. Citing studies
that identified the importance of the disulfide bonds in maintaining a rigid structure
and the α-helix initiated by proline in restricting the peptide’s length, the team
decided to conserve the C2, C3, P6, C8, and C16 residues during their simulation.
The plan was to allow the mutation of all other residues subject to the constraint that
a residue’s polarity and/or charge be conserved. That is, the polar and/or charged
S4, N5, H9, E11, H12, S13, and N14 residues could mutate into polar and/or charged
amino acids and the nonpolar G1, V7, L10, and L15 residues could mutate into
nonpolar amino acids (excluding proline). However, the resulting mutation space
consisted of an intractable 80 billion (84 ∗ 117) peptides. To make the experiment
tractable, the mutable residues were reduced to N5, H9, L10, E11, H12, and L15 and
mutation into C was excluded. This reduced the mutation space to a collection of
640,000 (82 ∗ 104) peptides. The HTVS capabilities of DockoMatic 2.0 were to be
used to investigate the library.
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Peptides are rarely used as pharmaceuticals since most are rapidly inactivated by
gastrointestinal enzymes. As such, the second step in the workflow was using the
top hits from the first step as the structural basis of a ligand-based HTVS of the
PubChem Compound database. The PubChem project contains an online tool for
searching any of the PubChem databases. The team planned to use the online tool
to perform a 3-D shape-based similarity search against the top α-CTx MII mutants.
Molecular docking calculations would be performed to predict the binding affinity
(to the α3β2-nAChR) of the identified small molecules. Lab-based techniques could
then be used to verify the computational predictions, and the entire workflow could
be used to probe the more biologically relevant nAChR α6α4β2β3-isoform in order
to identify drugs for treating Parkinson’s disease.
1.3 CAEPIDR
CAEPIDR was developed to facilitate the experiment described in Section 1.2. Fol-
lowing experimental validation, the software that was developed for the α3β2-nAChR
experiment was generalized and incorporated into DockoMatic. The resulting pro-
gram, DockoMatic 2.1, is a powerful tool for exploring a receptor’s conformational
binding space with peptide mutation and identifying small molecule drugs for disease
treatment.
In total, this thesis represents 4 major contributions to the field of biochemistry.
First, the identification of small molecule drugs with a high binding affinity to the
nAChR α3β2-isoform. Second, GAMPMS, a model for efficiently and accurately
searching a peptide’s mutation space for receptor binding affinity. Third, a procedure
for performing fast 3-D shape-based similarity searches over molecular databases.
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Last, an extension to DockoMatic that includes an implementation of the GAMPMS
model and the 3-D shape-based search procedure.
The body of this thesis has been divided into 2 chapters. Chapter 2 details the
Genetic Algorithm Managed Peptide Mutant Screening (GAMPMS) model, which
was developed to increase the throughput of DockoMatic’s virtual screening process
when screening peptide mutant libraries. The general model, as well as an imple-
mentation of it, are explained and experimental results are shown that demonstrate
its soundness. A GAMPMS of the 640,000 α-CTx MII peptide mutant library was
performed, in fulfillment of the workflow from Section 1.2, and is described. The
results of the search are also presented. The chapter ends with a usage case of
DockoMatic 2.1, demonstrating how to use the integrated GAMPMS program.
PubChem’s online search tool does not work with small peptides such as the α-
CTx MII peptide mutants, and an alternative tool was needed to search the database.
Chapter 3 details the procedure used to search a local copy of the PubChem Com-
pound database. The procedure is presented in the form of several pseudo-code algo-
rithms with accompanying textual explanations. The PubChem Compound database
search, for small molecules that were structurally similar to the α-CTx MII mutants,
is described and the identified small molecules are presented. The chapter ends with
a usage case of DockoMatic 2.1, demonstrating the use of the SimSearcher tool.
SimSearcher can be used to quickly search local molecular databases (sdf format) for
structurally similar 3-D conformers.
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CHAPTER 2
GENETIC ALGORITHM MANAGED PEPTIDE
MUTANT SCREENING
2.1 Introduction
2.1.1 Motivation
DockoMatic 2.0 facilitates the screening of large peptide mutant libraries by enabling
the following workflow: enumerate the peptide ligands in a file, enter the receptor
and specify its binding domain as a set of grid coordinates, select the number of GA
runs to be used in AutoDock simulations, and submit the jobs to run on a server.
However, the simultaneous submission of hundreds of thousands of jobs is likely to
overload the cluster’s scheduler and upset its administrators. In practice, screening a
large library with DockoMatic 2.0 requires the user to partition the library and submit
each partition separately, usually after some of the previously submitted jobs have
completed. Since most users of DockoMatic 2.0 are not expected to have scripting
skills, this procedure is not viable for large libraries.
Even with a script to monitor job submissions, performing molecular docking
calculations for hundreds of thousands of ligands is computationally expensive. For
example, using AutoDock 4.0 to simulate the binding of each of the 640,000 α-CTx
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MII mutants on a 122 core cluster1 (using 100 GA runs) would require:
1. ≈ 2 years to complete
2. ≈ 73.7 Terabytes of storage
3. 5246 partitions (for user submission)
assuming that each pose evaluation would requires 2 minutes to complete.
For many reasons, perhaps the most important of which is the inability of most re-
searchers to access a large quantity of computing power for a long period of time, these
requirements made the experiment intractable. An alternative method was needed
to reduce the time and computational requirements. To address these problems, we
asked the following question:
How can the α-CTx MII mutant library be screened in less time, with less
computational resources, and without the need for human supervision?
One solution that immediately presented itself was to reduce the number of pose
evaluations per ligand. This would result in a proportionate reduction in the time and
storage requirements for the screening. However, using only a few pose evaluations
would still require 5,246 submissions and would undermine the accuracy of the study.
2.1.2 Related Work
Generally applicable HTVS techniques exist that can greatly increase the throughput
of virtual screenings. Typically, these approaches use machine learning algorithms to
predict the binding affinity of new compounds. The affinity of docked ligands is used
1The size of the Computer Science Department’s in house (beowulf) cluster at Boise State
University
14
to train the algorithms. Once trained, the algorithms are several orders of magnitude
faster than molecular docking techniques. As such, they can be used to screen huge
libraries that would be intractable to screen with traditional docking methods.
In one such approach, molecular docking techniques are used to assess the binding
affinity of a subset of a compound library. The docking results are then used to train
a random forest algorithm which is used to predict the binding affinity of the library’s
remaining compounds [28]. Using this approach, Plewczynski was able to find 60%
of the active compounds for a protein target when docking only 10% of the library.
Random forests have been shown to compare favorably to other methods for screening
molecular databases [29, 30]. Cherkasov et al. took a similar approach but built a
QSAR regression model instead of a random forest. The QSAR was then used to
predict the binding affinity for new compounds based on their 2D descriptors [31, 32].
The approach was able to reduce the time required for the screening of a 90,000
compound library (of potential human sex hormone-binding globulin (SHBG) binders)
by 40% while finding 4 structures that were SHBG binders with high micromolar
affinities. Different regression models, decision trees, neural networks, and many
other classifiers from machine learning have been used to a similar effect. Ma [33]
and Melville et al. [34] have both surveyed applications of machine learning classifiers
within the field of HTVS, and the interested reader is encouraged to review their work
for a more detailed treatment of the subject.
A genetic algorithm (GA) is another popular machine learning technique that
has found application in computational and combinatorial chemistry. Sheridan et
al. [35, 36] have used a GA to construct a library of synthesized oligomers from large
sets of simple chemical fragments. The GA was used to optimize the diversity of
the library’s members with the assumption that maximum structural diversity would
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result in the broadest coverage of the bioactivity space. The SELECT program [37]
searches for optimally diverse libraries using a product-based approach to library
design. With SELECT, a fully enumerated virtual library can be searched with a
GA for combinatorial subsets that are optimally diverse. Studies demonstrating low
hit rates yielded by maximally diverse libraries [38, 39] have resulted in the extension
of SELECT to support multiobjective optimization. Fonseca and Fleming give a
detailed survey of various approaches to multiobjective optimization [40], and several
programs have been created to perform multiobjective optimization [41, 42].
2.1.3 Genetic Algorithm-Based Searching
While machine learning algorithms can be used in place of traditional docking meth-
ods in order to increase the throughput of a screen, they are less accurate. Addition-
ally, the score that is assigned by a custom implementation (using a unique training
set) of a machine learning algorithm to a ligand/receptor binding is rather meaningless
in the context of a scientific community. In contrast, reporting an AutoDock score is
useful since anyone can use AutoDock and attempt to replicate the reported results.
Ultimately, an unsupervised algorithm was needed that could use the results of
previous docking jobs to make an informed decision as to which mutations would
increase the peptide’s binding affinity and which would decrease it. Algorithm 1
illustrates the essential characteristics of the desired model, which can be implemented
effectively with a GA.
A GA is a non-deterministic, iterative search heuristic that uses techniques derived
from natural evolution to search for an optimal solution to a given problem. A
GA searches by first randomly generating a collection (population) of hypotheses
(individuals) and then iteratively deriving a new population from the current one. A
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Algorithm 1 Heuristic Screen
Dock random peptides from the library
while improvement in top affinity ligands do
Infer goodness of mutations using data from docked peptides
Generate peptide mutants which could test inference model
Dock those mutants
end while
new population is built by applying a set of operators, known as genetic operators, to
the members of the current population. Common genetic operators include: mutation,
where individuals experience slight alterations; crossover, where pieces of the best
known individuals are recombined to form new individuals; and selection, where
individuals meeting some criteria are transferred to the next population. Central
to GAs is the ability to assess the goodness (fitness) of an individual. In the case of
molecular screening, the fitness of a ligand is likely to be directly proportional to its
binding affinity with a target receptor. A GA continually derives new populations
until some stopping criteria is met: typically when a set number of iterations have
occurred or there is stagnation in the fitness of the top individuals.
A genetic algorithm can be used to perform a heuristic HTVS of a peptide mutant
library, reducing the time and computing resources required for the screening without
the need for algorithm training.
The Genetic Algorithm Managed Peptide Mutant Screening (GAMPMS) model
was built to demonstrate the soundness of this hypothesis. In the GAMPMS model,
a GA manages a structure-based HTVS of a collection of peptide mutants. The
GA iteratively docks small collections of compounds and uses the binding affinities
of previously docked compounds, in tandem with techniques derived from natural
evolution, to select compounds for subsequent docking calculations. This approach
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compares favorably to other machine learning methods, when screening large peptide
mutant libraries, since it does not require training. The GA handles job submission
and monitoring, allowing researchers to focus instead on setting up the next phase of
the study.
2.2 GAMPMS
Algorithm 2 GAMPMS
stagnant rounds, i← 0
populationi ← generate random peptides
while stagnant rounds < MAX do
fitness evaluation of populationi
if change in highest affinity ligands then
stagnant rounds = 0
else
stagnant rounds+ +
end if
populationi+1 ← genetic operators(populationi)
i = i+ 1
end while
The GAMPMS model is shown in Algorithm 2, and a possible iteration is il-
lustrated in Figure 2.1. As mentioned previously, the GAMPMS model uses a
genetic algorithm to iteratively dock small collections of compounds (populations).
Every population has the same number of peptides whose binding affinity with the
target receptor is unknown, so a constant number of docking jobs are submitted at
the beginning of each iteration. The GAMPMS model is therefore self-throttling,
requiring no submission management on behalf of the user.
In GAMPMS, peptide mutant libraries are defined as a base peptide and a set
of mutation constraints. Mutation constraints specify which residues are subject
to mutation (mutable) and which amino acids can be substituted for each mutable
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residue. As an example, the 640,000 α−CTx MII mutant ligand library from Section
1.2 is defined in Table 2.1.
Base Peptide: α-CTx MII
Mutable Residue Substitutable Amino Acids
N5 R,N,D,E,Q,H,K,S,T,Y
H9 R,N,D,E,Q,H,K,S,T,Y
L10 A,G,I,L,M,F,W,V
E11 R,N,D,E,Q,H,K,S,T,Y
H12 R,N,D,E,Q,H,K,S,T,Y
L15 A,G,I,L,M,F,W,V
Table 2.1: The 640,000 α−CTx MII mutant ligand library defined as a base peptide
and a set of mutation constraints.
To be consistent with the GA terminology from before, peptide mutant screening
is envisioned as an optimization problem. An individual is a sequence of amino
acids such that there is one amino acid associated with each mutable residue in the
peptide mutant library’s definition. The goal of a peptide mutant screening is to find
an individual that, when the individual’s amino acids are substituted for the base
peptide’s mutable residues, results in a peptide with an optimal binding affinity with
the target receptor.
Figure 2.1: A possible iteration of GAMPMS
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2.2.1 Implementation of the Genetic Algorithm
Representation of an Individual
In the GA that was integrated into DockoMatic 2.1, each individual (peptide mutant)
is represented as the sequence of amino acids that are substituted for the base
peptide’s mutable residues. Since the base peptide is assumed to be the same for
all mutants, it is not necessary to incorporate it into the representation. Using the
single letter amino acid symbols, each individual can be represented as a character
array.
Fitness Evaluation
In DockoMatic’s GAMPMS implementation, evaluating the fitness of an individual
is a two-step process. In the first step, a pdb file is built for each individual by
submitting the individual’s set of mutations, along with the base peptide, to the
Treepack program. In the second step, the pdb file is used as the ligand for a
molecular docking simulation against the target receptor. AutoDock is used to dock
the ligand against the target receptor, and the Gibbs energy of the highest affinity
pose is considered the fitness value for the individual. The number of pose evaluations
to be used in each AutoDock simulation is configurable.
Genetic Operators
Three genetic operators are used in DockoMatic 2.1’s GA.
Elitism The first operator is elitism: a special case of the more general selection op-
erator. As previously mentioned, the selection operator selects individuals, based on
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some user-defined criteria, to be carried over to the successive population. In the case
of elitism, that criteria is fitness ranking within the population. In DockoMatic 2.1,
the elitism operator selects the top elite factor ∗ 100% of a population’s individuals
and adds them to the successive population.
Crossover The second genetic operator is two parent, two offspring N-point crossover
using a fitness proportionate selection scheme. The implemented two parent, two
offspring N -point crossover occurs in three steps. First, a selection scheme is used
to chose two individuals (the parents) from the current population. Since a fitness
proportionate selection scheme is used, the probability of an individual being chosen is
directly proportional to its fitness ranking within the population. In the second step,
a set of N indices are chosen from within a parent’s range ([1, individual length]) and
both parents are split into N + 1 pieces according to the indices. Finally, the pieces
from both parents are combined, in an alternating fashion, to make two different
offspring that share features of both parents. Figure 2.2 shows an example of two
parent, two offspring, 2-point crossover.
In DockoMatic’s implementation, the indices defining the splits are chosen ran-
domly for each pair of parents. The number of indices (N) is configurable but defaults
to N = b individual length
2
c. Recall that individual length is the number of mutable
residues in the peptide mutant library’s definition.
Mutation The final genetic operator is mutation, a process whereby each amino
acid in an individual’s sequence has a small chance of being replaced by a different
amino acid from the substitution set of the associated mutable residue. Two versions
of the mutation operator were implemented. In the first version, the probability of
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Figure 2.2: A pictorial representation of 2 parent, 2 offspring, 2-point crossover. Two
individuals from the current population are split into pieces and those pieces are
reassembled, in an alternating fashion, into 2 new individuals.
an amino acid being replaced by another amino acid was proportional to the historic
probability of such a mutation occurring. The historic probabilities were derived from
the PAM 1 mutation matrix (see Figure 2.3). In the second version, an amino acid
had an equal chance of changing into any of the other amino acids in the associated
residue’s substitution set. The different versions were used in multiple screens of
a known affinity peptide mutant library (see Section 2.3). It was found that the
uniform mutation technique had a (statistically insignificant) lower average number
of docking calculations for a screening that found similar affinity ligands. Due to its
relative simplicity, uniform mutation is used in DockoMatic 2.1’s GA.
In DockoMatic 2.1, the user can specify themutation rate, which is the probability
that any amino acid is altered during the mutation operation.
Terminating Condition
A genetic algorithm iteratively builds new populations, using a set of genetic oper-
ations, until some criteria is met (see Algorithm 2). In DockoMatic 2.1, the genetic
algorithm stops generating new populations when there has been no change in the
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Figure 2.3: The PAM 1 mutation matrix. The number at coordinates row, col
represents the average number of times that the amino acid row has mutated into
the amino acid col for every 10,000 mutations that have been identified.
top X highest affinity peptides over the last λ iterations. Intuitively, using larger λ
values will increase the probability of finding the highest affinity ligands in the library,
whereas using lower λ values will reduce the screening’s run time. The values of both
top X and λ are configurable.
Parameters
In review, the behavior of the GA is parameterized with 5 numeric values, represent-
ing:
elitism factor : the percent of the population’s top individuals that are carried over
to the successive population.
mutation rate : the probability of a mutation occurring within an individual.
top X : the number of optimal peptide mutants to identify.
|ρ| : the population size.
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Name Size Residues Amino acids
library64 64000 N5 -
library46 46656 N5 D
library32 32768 N5 D,H
library25 25088 N5 D,H,V
library16 16807 N5 D,H,V,Q
library8 8000 N5,L15 -
library5 5382 N5,L15 D
Table 2.2: Additional constraints were added to the 640,000 α − CTx MII mutant
library in order to create smaller libraries. This table lists, for a specific library, the
residues that were no longer deemed mutable and the amino acids that were no longer
substitutable.
λ : the GA stops after λ iterations of no change in the top top X individuals.
|ρ| = 50 and top X = 10 were used as the default values in the experiments in
section 2.3. The following notation is used to list the additional parameter values for
a GAMPMS experiment: { elitism factor,mutation rate, λ }.
2.3 Validation
For proof of concept, the GAMPMS implementation was used to screen libraries of
α−CTxMII mutants for binding affinity towards the α3β2 isoform of rat neuronal
nAChR. Each library was a subset of the 640,000 α−CTxMII mutant library from
Section 1.2; the libraries are defined in Table 2.2.
The most important subset was the 64,000 mutant library (library64) resulting
from the removal of N5 from the set of mutable residues. Since it was small enough
to screen exhaustively but large enough to yield interesting results, it was used for
most of the experiments in this section.
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2.3.1 Experimental Setup and Evaluation Metrics
The soundness of GAMPMS was assessed by comparing its results to those of an
exhaustive, structure-based HTVS (i.e., molecular docking calculations were per-
formed for each compound) of the same library. The binding energy of the top hits
and the number of docking calculations performed were the focus of the assessment.
Comparison of the number of docking calculations was straightforward; every peptide
was docked with the exhaustive approach whereas only a fraction of them were docked
with GAMPMS. The number of docking calculations performed by a GAMPMS is
reported as a percent of the library’s cardinality, denoted %Docked.
Comparison of the binding affinity of the top hits is a little more complicated.
We define Σx,r,s as the summation of the binding energy, against receptor r, of the x
best peptides identified by a HTVS s. The similarity in binding affinity between a
GAMPMS and an exhaustive screening is measured as:
%Affinity =
Σx,r,GAMPMS
Σx,r,exhaustive
.
All %Affinity scores in the current study use x = 10 and r = α3β2 nAChR.
AutoDock 4.0 was used, with 30 pose evaluations per docking (i.e., ga runs =
30), for the exhaustive, structure-based HTVS of library64 against the α3β2 nAChR
model. A fitness map, which associated a peptide to its highest affinity score from
AutoDock, was constructed from the HTVS results and used as the fitness function
for each GAMPMS mentioned below. This map allowed a GAMPMS to run in a
fraction of a second and removed the inconsistency from AutoDock scoring.2
The results of a GA are dependent on the values of its parameters (e.g., mutation rate,
elite factor, λ, etc.) and the pseudo-random numbers generated during the crossover
2If a ligand is given a different fitness score in each screening, it can be difficult to compare the
results of those screenings.
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and mutation operators. As such, a meaningful assessment of GAMPMS required
multiple screenings of each library. A given GAMPMS, identified by the library
screened and the parameter values used, was repeated multiple times to isolate the
variance resulting from the random number generator. We report the results of 1910
GAMPMS’s of library64 and 10 GAMPMS’s of each of the smaller libraries. The
fitness map from above served as the basis of the comparison between a GAMPMS’s
identified peptides and those that would have been identified by an exhaustive screen-
ing.
2.3.2 GAMPMS Consistency
The consistency of GAMPMS, as it relates to the %Affinity and %Docked scores,
was assessed with 300 independent GAMPMS’s of library64. For 100 of the exper-
iments, the set of parameter values { .2, .02, 2} was used to produce low %Docked
scores. The more general set of parameter values { .2, .05, 12 } was used for an addi-
tional 100 experiments. The last 100 experiments were run with a set of parameter
values, { .3, .08, 25 }, selected to yield a high %Affinity score. The results are
captured by the histograms in Figures 2.4 and 2.5. Figure 2.4 shows the frequency
of %Affinity scores across the 300 experiments, whereas Figure 2.5 shows the fre-
quency of %Docked scores across the same experiments. In both of these figures,
the height of bar[i] represents the fraction of GAMPMSs that resulted in a score
x : bar[i] ≥ x ≥ bar[i−1]. The exception to this rule is bar[0], whose height represents
the fraction of GAMPMSs that resulted in a score x : x ≤ bar[0]. For perspective,
100 screens were performed by docking 5,700 (the largest number of peptides docked
during the 300 experiments from above) random members of library64. This random
sampling resulted in a mean %Affinity score of 91.7 (σ = 1.3).
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Figure 2.4: A histogram representing GAMPMS’s soundness when screening
library64. The height of a bar represents the frequency of the range of %Affinity
scores. The blue bars summarize the data from 100 experiments with “low % Docked”
parameter values, the yellow bars summarize the data from 100 experiments with
“high %Affinity” parameter values, and the orange bars summarize the data from 100
experiments with more neutral parameter values. The lowest recorded %Affinity
score across all 300 screens was 94.05.
Figure 2.5: GAMPMS’s efficiency when screening library64. The x-axis shows the
percent of the library that was docked and the y-axis shows the associated frequency.
The color scheme is the same as detailed in Figure 2.4.
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Figures 2.4 and 2.5 demonstrate that GAMPMS can consistently find some of
the highest affinity ligands while performing docking calculations for a relatively
small number of the peptides. Moreover, the results indicate that the variance in
performance can be tuned with a single parameter. Specifically, increasing λ had the
effect of decreasing the variance in the %Affinity scores and decreasing λ had the
effect of decreasing the variance in the %Docked scores.
2.3.3 GAMPMS Scalability
|ρ| vs Performance
To assess how the GAMPMS implementation scaled with population size, |ρ|, 1,600
independent GAMPMSs of library64 were performed. The value of |ρ| was changed
for every 100 screens. The parameter values { .25, .05, d900|ρ| e } were used for all
1,600 GAMPMSs. The %Docked score and the number of iterations required for
convergence were recorded and are displayed in Figure 2.6.
The time required to apply the genetic operators, submit docking jobs, and parse
the fitness values is insignificant compared to the time required for the molecular
docking simulations. As a result, the approximate run time of a GAMPMS can be
expressed with Rquation 2.1.
timetotal = iterations ∗
⌈
timejob ∗ |ρ|
available cores
⌉
(2.1)
where timejob is the amount of time required to dock a ligand to a receptor with
AutoDock.3
3This time is dependent on the number of pose evaluations being used; 1-3 minutes per pose
evaluation depending on your system’s speed.
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Figure 2.6: GAMPMS’s performance measures based on the number of processing
cores used, |ρ|. The y-axis shows the number of iterations (submissions) needed for a
GAMPMS to converge. Each diamond represents the mean value, for the associated
ρ, from 100 GAMPMSs of library64.
It can been seen from Equation 2.1 that the lowest run time can be achieved by
choosing the population size, |ρ|, to be less than or equal to the number of available
processing cores. In this case, all docking jobs can be run in parallel. Selecting a
larger value of |ρ| will at least double the run time of the screen.
Library Size
To approximate how the %Docked score scales with larger libraries, library64, library46,
library32, library25, library16, library8, and library5 were each screened 10 times with
the GAMPMS implementation. Each screening used the same set of parameter values:
|ρ| = 30, topX = 5 and { .2, .04, 5 }. The %Docked score from each GAMPMS was
plotted and is shown in Figure 2.7.
The inverse relationship between the size of a library and the %Docked score
indicates that the number of docking jobs required for a GAMPMS increases more
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Figure 2.7: The %Docked scores from 10 GAMPMSs of different sized libraries. Each
diamond represents a %Docked score.
slowly than does the cardinality of the compound library. So the average %Docked
score for a GAMPMS scales very well with library size. It is also interesting to note
the negative correlation between the variance in the %Docked scores and the size of
the library. If the trend holds for larger libraries, it might be possible to accurately
predict the number of iterations required for the screening to complete.
2.4 A GAMPMS of the 640,000 α-CTx MII Mutant Ligand
Library
The GAMPMS implementation was used to screen the 640,000 α-CTx MII mutant
library for binding affinity to the α3β2 nAChR. The results from Section 2.3 were used
to identify a set of parameter values that would yield peptides with a relatively high
binding affinity without requiring more than a week to run. The GA was configured
to mutate one in every 50 amino acids, carryover the top 40% of each population,
use two parent, two offspring, 3-point crossover, and attempt to identify a set of 50
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Peptide Energy (kcal/mol)
MII:N5Y:H9Y:L10W:E11T:H12N -21.07
MII:N5Y:L10W:E11Q:H12S:L15F -20.91
MII:N5Y:H9Y:L10W:E11Q:H12S:L15V -20.91
MII:N5Y:L10W:E11S:H12S:L15F -20.88
MII:N5Y:L10W:E11S:H12S:L15W -20.79
MII:N5Y:H9S:L10W:E11K:H12S:L15F -20.74
MII:N5Y:L10W:E11Y:H12S:L15V -20.73
MII:N5Y:H9K:L10W:E11S:H12N:L15G -20.71
MII:N5Y:H9N:L10W:E11S:H12S:L15W -20.68
MII:N5Y:L10W:E11K:H12S:L15G -20.66
MII -12.38
Table 2.3: The 10 highest affinity peptides found with a GAMPMS, the base peptide
(α-CTx MII), and their associated Gibbs free energy of binding.
optimal peptides. The GA terminated after it went 5 rounds without an improvement
in the binding energy of the 50 top peptides.
The screening was performed using 128 cores on Idaho National Laboratory’s
(INL’s) Fission cluster.4 40 pose evaluations were used in the AutoDock docking
simulation for a ligand/receptor binding. Had DockoMatic 2.0 been used for the
HTVS, it would have required 5,000 submissions (of 128 AutoDock jobs) and roughly
292 days. Instead, the GAMPMS implementation submitted 73 groups of 128 jobs
(for a total of 9,344 molecular docking jobs) and finished in 4 days and 6 hours. The
10 highest affinity mutants identified by GAMPMS, as well as the α-CTx MII peptide
(for reference), are shown in Table 2.3.
4The screening was funded as part of the Idaho University Consortium
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2.5 Usage: Screening Peptide Mutants with DockoMatic 2.1
A workflow has been included in DockoMatic 2.1 to facilitate the screening of large
peptide mutant libraries. The workflow is illustrated here by walking through the
setup of a GAMPMS of the 640,000 α-CTx MII library from Section 1.2.
To screen a peptide mutant library, DockoMatic 2.1 must be loaded and the
receptor’s pdb and gpf file, the output directory, and the ligand’s (base peptide’s)
pdb file must be entered in the associated fields. The number of AutoDock cycles
(pose evaluations) must be specified, as well as any special options for the swarm
utility. When these steps are completed, the “Mutation Screening” check box can be
marked to bring up the peptide mutant screening wizard (thewizard). Figure 2.8
shows what DockoMatic’s main window looks like when setting up a GAMPMS of an
α-CTx MII (MII) mutant library against the α3β2 nAChR (A3B2 2br8).
thewizard was designed to simplify the process of defining the peptide mutant
library and, if desired, to configure the genetic algorithm to be used for a GAMPMS
of the defined library.
2.5.1 Defining the Peptide Mutant Library
Recall that a peptide mutant library can be defined as a base peptide and a set of
mutation constraints, which specify the mutable residues and the amino acids that
can be substituted for each mutable residue. The base peptide is input as the ligand
in DockoMatic’s main screen, and the mutation constraints are specified in the first
two steps of thewizard. In the first step, residues belonging to the base peptide are
selected for mutation. In the second step, a set of amino acids is associated with each
of the mutable residues.
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Figure 2.8: The main window component of DockoMatic 2.1. To screen a peptide
mutant library, the user needs to input the necessary data files and then select the
“Mutation Screening” option, which has been highlighted in red in the picture.
33
Mutable Residues
When thewizard is first loaded, the base peptide’s amino acid sequence is parsed
from the pdb file and displayed as a list of residues. Residues are deemed mutable if
they are selected in the list. One can use the standard multiselect and range select
features (respectively, CTRL + click and select first, hold SHIFT, select last) to select
residues for mutation. The “Go To” button is useful when dealing with a larger base
peptide (more residues). The button can be used to center the list on a certain
residue (enter its index and click “Go To”) or on the next type of residue (enter the
single letter representation for the amino acid and hit “Go To”). For convenience,
the currently selected residues will be displayed at the bottom of the screen.
To setup the GAMPMS for the the 640,000 α-CTx MII mutant library from
Section 1.2, hold down the CTRL button, click the N5, H9, L10, E11, H12, and L15
residues, and then click Next. Figure 2.9 shows the completed step before clicking
Next.
Mutation Constraints
Once the mutable residues have been selected, a peptide mutant library can be
defined by constraining the mutation of each mutable residue. This is achieved
by entering a substitution set for each mutable residue. One specifies a mutable
residue’s substitution set by selecting the mutable residue from the top list, selecting
the substitution set from the lower list (using the same list features described above),
and then hitting the “Bind Constraints” button. The same substitution set can be
easily assigned to multiple residues by multiselecting from the residue list. Figure
2.10 shows the nonpolar residue substitution set selection for the 640,000 α-CTx MII
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Figure 2.9: The first step in the Peptide Mutant Screening wizard. The user selects
residues from the base peptide that can be mutated during the experiment. The Go
To button can be used to focus the list on an acid type or index. Clicking the “Next”
button goes to the Mutation Constraints screen.
mutant library.
A peptide mutant library has been fully defined when a substitution set has been
selected for each mutable residue. Clicking “Finish” returns the user to the main
DockoMatic screen, where they can perform an exhaustive structure-based screen of
the library by clicking the “New Job” button. Alternatively, clicking the “Next”
button allows the user to configure a GA for a GAMPMS of the library.
2.5.2 Setting the GA’s Parameters
Configuring a GAMPMS requires specifying |ρ|, top X, and the desired balance
between the opposing goals of minimizing the number of docking calculations required
for the screening and maximizing the estimated binding strength of the resulting
ligands. The population size, |ρ|, determines the number of molecular docking jobs
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Figure 2.10: The second step in the Peptide Mutant Screening wizard. The user
assigns a substitution set to each mutable residues by selecting the relevant list
elements and hitting the Bind Constraints button. The resulting library can be
screened exhaustively (“Finish”) or with a GAMPMS implementation (“Next”).
that will be submitted at each iteration. To minimize the time required for a
GAMPMS, |ρ| should not exceed the number of processors that can be dedicated
to the screening. As mentioned in Section 2.2.1, the GAMPMS process ends when
there has been no change in the top X highest affinity ligands in the last λ rounds.
Thus, the value of top X affects both the number of iterations that will be generated
and the cardinality of the “optimized” result set.
In Section 2.2.1, it was shown that a GA’s performance can be configured by
specifying values for genetic operators’ parameters and the termination condition.
However, part of DockoMatic’s purpose is to make molecular docking tools accessible
to students. It is assumed that DockoMatic 2.1 users will be unfamiliar with GAs and
thus unable to configure a GA’s parameters to meet their screening goals. So instead
of inputting numeric values for unfamiliar parameters, a novice user tells thewizard
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Figure 2.11: Configuring a GAMPMS requires setting the population size, top X
(Result Set Size), and the sliding bar’s position. The remaining parameters are
generated automatically based on these 3 values. The generated values can be
viewed/modified by clicking Next, or the GAMPMS can be instantiated by clicking
Finish.
how to weigh the opposing goals of minimizing the number of docking calculations
required for the screening and maximizing the estimated binding strength of the
resulting ligands. This is achieved by adjusting thewizard’s sliding bar (see Figure
2.11). Appropriate values for elitism factor,mutation rate, and λ are generated
automatically.
When all 3 values have been input, the generated parameter values can be viewed
and/or modified by clicking Next. Alternatively, the GA can be instantiated by
clicking Finish. Clicking the “New Job” button from the main DockoMatic screen
will start a GAMPMS of the defined library.
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2.6 Conclusion
GAMPMS uses a genetic algorithm to manage a structure-based high throughput
virtual screening of a peptide mutant library. It is capable of reducing the number
of molecular docking calculations required to screen a 640,000 peptide library by
roughly 98.5% while finding ligands with high binding affinity with the target receptor.
Its performance is easily configurable, allowing the user to prioritize the number
of docking calculations performed or the binding affinity of the identified peptides.
GAMPMS scales well with the size of the peptide mutant library, exhibiting an inverse
relationship between the size of the library being screened and the percent of the
library’s compounds that need to be docked.
GAMPMS has the advantage of significantly reducing the number of docking
calculations required for structure-based HTVS. In comparison to other approaches,
GAMPMS does not require training or any form of human supervision. Instead,
GAMPMS iteratively docks populations of mutants using evolutionary techniques and
the binding energies of previously docked mutants to select compounds for subsequent
docking simulations. The types of libraries that can be screened with GAMPMS
are limited to combinatorial libraries such as those that result from mutating a
molecule. As with most other non-trivial heuristic searches, there is no guarantee
that a GAMPMS will find the highest affinity ligand from a library. The integration
of the GAMPMS model into DockoMatic 2.1 represents an important extension to
the suite’s investigative potential.
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CHAPTER 3
SIMILARITY SEARCH
3.1 Introduction
3.1.1 Motivation
Receptor-driven drug repurposing typically involves a ligand-based HTVS of small
molecule databases. Many small molecule databases exist, including DrugBank, Pub-
Chem, BindingDB, ChemSpider, and the Beilstein and Gmelin databases (available
through Reaxys), which provide web-based tools for performing substructure and
molecular similarity searches. However, each database uses a different interface and
different algorithms for their search. This can be problematic when one wishes to
perform a specific type of search over a database that contains the necessary data but
not the tools.
Having identified a set of peptides with a high-binding affinity to the target
receptor, the next step in the workflow (described in Section 1.2) was the identification
of small molecule drugs that closely resembled the 3-D shape of the α-CTx MII mutant
ligands. This was to be achieved using PubChem’s online search tools. The tools are
accessible free of charge, courtesy of the NIH, and can be used to search any of the
PubChem databases. The compound structure similarity search was identified as the
most appropriate for our experiment. The 200 highest affinity α-CTx MII mutants
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from the GAMPMS were used as input for the search. However, it was discovered
that PubChem’s 3D search, which is geared towards small, drug-like molecules, can
only generate a model for compounds containing less than 16 rotatable bonds. The
α-CTx MII mutants had at least 20 rotatable bonds, and as a result the tool failed
to generate a model for any of them. An alternative means of searching PubChem
was needed.
While there are many chemical databases, PubChem is arguably the most useful
for drug repurposing. It contains patent information, bioassay results, bioactivity
data, and structural information for over 51 million small molecules, including drugs
that have already been approved by the FDA.1 For these reasons, searching PubChem
was a vital part of the research project.
PubChem provides an FTP service for downloading their Compound database,
but the question remained:
How can a local copy of the PubChem database be quickly searched for molecules that
are “similar” to our small peptides?
First, a means of assessing similarity was needed. PubChem 3D uses volume
overlay techniques to compare each molecule in the database to a set of (a few
thousand) structurally diverse reference molecules. A binary fingerprint is then
constructed for each molecule by associating a bit with every reference molecule. If a
reference molecule is similar to a molecule, the corresponding bit is set. When all the
molecules have a fingerprint, the similarity between molecules is quickly assessed using
the Tanimoto coefficient (shown in Equation 3.1) to compare their binary fingerprints.
1Although all 4 types of information are not available for all molecules
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Tanimoto =
AB
A+B − AB (3.1)
where A and B are the counts of fingerprint set bits in the molecule pair (respec-
tively) and AB is the count of bits in common.
Generating the fingerprint for every molecule is a computationally demanding
endeavor, but they can be precomputed in an completely parallel manner. PubChem
3D used this technique to reduce the search time by two orders of magnitude [43].
However, we did not want to spend months determining reference shapes and gener-
ating fingerprints in order to search the database a few times. A different technique
was needed to assess similarity within the database.
3.1.2 Similarity Metrics
Ligand-based HTVS must use a similarity metric that is easy to compute (or at
least precomputable) and discriminative. Since ligand-based HTVSs are often used
to discover ligands with similar bioactivity, without needing to perform expensive
molecular docking calculations, similarity metrics account for ligand characteristics
that are thought to be important in determining binding properties. Metrics are
broadly classified as structure or (pharmacophore) feature based, although some
metrics handle both. Structure-based metrics assess the shape of a molecule using the
molecule’s 2-D or 3-D coordinates. Graph comparison techniques such as Maximum
Common Subgraphs [44, 45] and graph kernels [46, 47], regression models such as the
Quantitative Structure-Activity relationship (QSAR) model [48], and volume overlay
techniques are commonly used to assess molecular similarity [49]. Feature-based
metrics focus on the presence and location of chemical features (e.g., hydrogen donors
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and acceptors, ring centers, and charged atoms) that are needed to trigger a biological
response from a specific biological target. QSAR and graph techniques, which work
well with a descriptor-based representation, can also be used to assess feature-based
similarity.
The size of chemical databases (terabytes) often necessitates the use of molecu-
lar signatures: compact, trivially comparable entities that encapsulate a molecule’s
relevant features. Using signatures divides the work of searching into two steps:
signature generation and signature comparison. Signatures are typically designed to
transfer complexity from the comparison aspect and into the generation aspect. Since
signatures can be precomputed, search times are typically much faster when signatures
are used. PubChem 3D uses binary fingerprints, which require computationally
demanding volume overlay techniques to generate, as a molecule’s signature.
3.2 Search Model
It was hypothesized that a shape distribution technique [50] could be used to assess
3-D shape similarity between molecules. With a shape distribution technique, a
shape sampling function is used to construct a distribution of measurements. The
distribution serves as the molecule’s signature and a distribution difference measure,
such as the χ2 test, is used to quickly compare the signatures.
While distribution tests are fast, performing 51 million of them can take a sub-
stantial amount of time. Multilevel K-means clustering provided a sound method for
decreasing search time since it would allow a recursive search operation to compare
the target molecule with a subset of the clusters. This would reduce the number of
comparisons required and therefore the search’s run time.
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A model was devised to allow quick similarity searches, with any target molecule,
over local molecular databases. For clarity, using a molecule M as the basis of a
similarity search (i.e., searching with a target molecule M) over a database D is
equivalent to searching D for items that are similar to M . The model consisted of
three steps:
Map Map all molecules to signatures.
Cluster Cluster the signatures for quicker searching.
Search Map the target molecule to a signature and search the (clustered) database
for similiar signatures.
Map must occur first to make a search tractable. The Cluster step is optional
but highly recommended because of its ability to reduce search time by a few orders
of magnitude. The Map and Cluster steps are computationally expensive but only
need to be performed once per database and can be pre-computed. Search is the
end product of the process, allowing users to quickly perform molecular similarity
searches over the database.
3.2.1 Map
Generating signatures is an embarrassingly parallel problem, which is made even
simpler by the fact that molecular databases are typically downloaded as a collection
of data files. To quickly generate signatures, it is necessary to first partition the
database files to create a partition for each available processing core. Then, using a
function (map()) to generate a signature for a molecule, an instance of the Map DB
algorithm (Algorithm 3) can be run on each processor in order to generate signatures
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for the associated partition. The important work in the Map step occurs in the
function map().
Algorithm 3 Map DB
for each DB file ∈ partition do
for each molecule ∈ DB file do
mMolecule← map(molecule)
write(mMolecule)
end for
end for
map() is responsible for generating a molecule’s signature (mapping a molecule
to a signature). The signature needs to be both descriptive and easily comparable so
that a similarity metric can be discriminative and efficient, respectively. Signatures
can be pre-computed, making the computational complexity of their generation less
important than that of the similarity metric.
Shape Similarity
The shape distribution approach described in Section 3.3 was used to gauge the 3-D
shape similarity of two molecules. In this approach, a shape sampling function is
applied to a 3-D shape in order to attain a set of measurements. The distribution of
these measurements is used as the shape’s signature. Any distribution difference test
(e.g., χ2) can be applied to the two signatures to quickly judge the similarity of the
associated molecules. This approach has been successfully applied to the comparison
of 3-D protein structures [51]. The implemented shape sampling function measures
the euclidean distance between unique pairs of atoms within a molecule. The amount
of computation needed for sampling is configured by defining the number of samples
to take. Since most of the molecules within PubChem Compound are small (less
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than 50 atoms), it was feasible to generate a distribution using all N(N+1)
2
unique
measurements (N is the number of atoms in the molecule).
A distribution is represented as a histogram containing a constant number of
bins and a maximum measurement threshold. Algorithms 4 and 5 demonstrate the
process used to create a molecule’s shape signature. Algorithm 5 is used as map()
in Algorithm 3 to generate shape signatures for a group of data files. Four similarity
metrics were implemented for signature comparison: Chi Square, L1 norm, L2 norm,
and the Root of Products test. These distribution tests are described in Appendix A.
Algorithm 4 Shape Sample(molecule)
for each atomi ∈ molecule do
for each atomj ∈ molecule do
if i 6= j then
if NOT sampledList.contains((i, j)) then
measurements.add(L2Norm(atomi, atomj))
sampledList.add((i, j), (j, i))
end if
end if
end for
end for
return measurements
3.2.2 Cluster and Search
Clustering is an optional step, although it is highly recommended for shape-based
similarity searches. Without clustering, searching a database with molecule q re-
quires comparing the signature of q to every signature in the database. For the
PubChem database, this would mean performing 51 million calculations. Clustering
the signatures can reduce the number of similarity calculations by a few orders of
magnitude.
45
Algorithm 5 map(molecule)
ID ← molecule.getID()
measurements← Shape Sample(molecule)
bins← Integer[num bins]
for each measurement ∈ measurements do
i← 1
for 1 to num bins do
if measurement < (i ∗ bin width) then
bins[i] + +
BREAK
end if
i+ +
end for
if i > num bins then
bins[num bins] + +
end if
end for
for each bin ∈ bins do
bin← bin/measurements.size()
end for
return ID, bins
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Let us imagine dealing with a database containing |DB| signatures. If the database
is clustered with the K-means algorithm, where K = k1∗k2∗ . . .∗kn, then an effective
search could be performed with
≈ K + |DB|
K
(3.2)
similarity calculations by comparing the target molecule to each of the K cluster
centers and then to each of the ≈ |DB|
K
signatures within the cluster whose signature
was most similar to the target molecule. If |DB|  K, a single K-means clustering
would reduce the number of comparisons by a factor of K.
Nested (multilevel) clustering can be used to further reduce search time. In
multilevel clustering, most clusters contain subclusters. Algorithm 6 gives a pseudo
code algorithm for the idea, with a user calling NlevelCluster(N,DB) to perform N
level clustering with the K-Means clustering algorithm. A “Big Data” implementation
of the K-means clustering algorithm was used for generating the two outermost
clusters, whereas an in-memory implementation was used for subsequent clusters.
Both of these implementations are discussed in Appendix B.
Algorithm 6 NlevelCluster(level,DB)
KMeans Cluster(DB)
if level > 1 then
for each cluster ∈ DB do
NlevelCluster(level − 1, cluster)
end for
end if
If the DB database is clustered with n-level clustering, where level i has ki clusters
(recall K = k1 ∗ k2 ∗ . . . ∗ kn from above), then the approximate number of similarity
calculations required for an effective search is given by:
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≈
n∑
i=1
ki +
|DB|
K
(3.3)
As a result, the difference in the number of required signature calculations between
the n-level clustering and the single clustering is given by:
n∏
i=1
ki −
n∑
i=1
ki (3.4)
So if |DB| = 50 million and K = 20 ∗ 20 ∗ 20 = 8000, then multilevel clustering
can reduce the search time by ≈ 65%, compared to a single K-means clustering.
The idea used in the single level cluster search can be easily extended to handle
nested clusters. Algorithm 7 shows a recursive technique that can search a collection
of signatures that have been subjected to N-level clustering.2 To search with the
target molecule q, one would call Search(q,DB).
Algorithm 7 Search(q,DB)
if DB contains clusters then
for each cluster ∈ DB do
sim← similarity(q, cluster.getCenter())
if sim < CLUSTER SIMILARITY THRESHOLD then
Search(q, cluster)
end if
end for
else
for each signature ∈ DB do
sim← similarity(q, signature)
if sim < SIGNATURE SIMILARITY THRESHOLD then
write(IDsignature, sim)
end if
end for
end if
2including 0-level & 1-level clustering
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3.3 Searching PubChem Compound
PubChem’s FTP tool3 was used to download the most diverse conformer for each
molecule in the PubChem Compound database. The SDF directory contained 2,864
sdf files, with each covering a range of 25,000 Compound ID numbers (CIDs). For
various reasons, many hundreds of thousands of compounds have been removed from
PubChem since its creation, so there are gaps in the CID sequence and each sdf file
contains data for less than 25,000 molecules. The 2,864 sdf files, which required 300
GB of storage, were stored on INL’s servers.
Shape distributions (signatures) were created for the downloaded molecules. The
Euclidean distance between all the unique atomic pairings within a molecule was
used to sample the 3-D shape of the molecules. The distances were binned to create a
histogram distribution. Each histogram contained 10 bins and each bin had a width
of 1.5 units. Distances greater than 15 units were placed in the last bin. The 2,864 sdf
files were divided into 16 groups of 179 files and signatures were generated for each
group in parallel. This required 3 hours and produced a signature file corresponding
to each sdf file.
Searching the signature database with a single peptide required 24 minutes. To
reduce the search time, the signatures were clustered using multilevel K-means cluster-
ing. During clustering, the χ2 test was used to assess the distance between signatures.
As a result of the clustering, the signatures were divided into 50 clusters, where each
of those clusters contained 20 subclusters and each of those clusters contained 5
subsubclusters.
The clustered signature database was queried with the top 200 peptides from the
3get ftp://ftp.ncbi.nih.gov/pubchem/Compound 3D/01 conf per cmpd/SDF/*
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GAMPMS described in Section 2.4. When querying the database, the χ2 test was
used to compare the peptide to the center of each of the 50 outermost clusters. The
cluster whose center was closest to the peptide, and all clusters whose centers had
a similarity score (with the peptide) within .01 of that score, were searched. The
same process occurred with the 20 subclusters contained in each searched cluster,
and again with the 5 subsubclusters contained in each searched subcluster. When
a subsubcluster was searched, the peptide was compared to each signature in that
cluster. In this manner, the 100 molecules that were most similar to a peptide were
identified in a few seconds with only a few thousand distribution tests.
Duplicate molecules and those containing inorganic elements such as silicon were
removed from the 20,000 small molecule collection, leaving 1,320 small molecules.
Each of these small molecules was docked against the α3β2 nAChR model using
AutoDock with 40 pose evaluations. To identify only distinct scaffolds, the 1,320
molecules were clustered and the molecule with the highest binding affinity with the
α3β2 nAChR was selected from each cluster. In this manner, 128 molecules were
identified. The 12 highest affinity molecules from the set of 128 are shown in Figure
3.1.
3.4 Usage: Searching PubChem with SimSearcher
The SimSearcher tool has been implemented in DockoMatic 2.1 to perform quick
similarity searches over local molecular databases. In this section, SimSearcher is
demonstrated by walking through the mapping, clustering, and searching of the Pub-
Chem Compound database. The PubChem Compound database, which was already
downloaded for the experiment in Section 3.3, was stored in the PubChemData folder.
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(a) CID 10349665 (b) CID 11017883 (c) CID 11479396
(d) CID 19303596 (e) CID 19311642 (f) CID 22012526
(g) CID 25131416 (h) CID 46702076 (i) CID 50197859
(j) CID 23590164 (k) CID 54426994 (l) CID 57872389
Figure 1: 2 dimensional structures
1
Figure 3.1: Small molecule drugs with predicted high binding affinity for the α3β2-
nAChR.
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Figure 3.2: The user interface for the SimSearcher program. To run any step of the
program (i.e., map, cluster, search), a user clicks the associated button. Output is
displayed in the area above the buttons
3.4.1 Map
The Map wizard is used to map the database’s molecules to a database of shape
signatures. A user clicks the Map button at the bottom of the SimSearcher window
(see Figure 3.2) to start the wizard. In the Mapping wizard, one must specify the
molecular database, the output folder (where to put the signature database), the type
of signature to generate, and the submission parameters.
For the demonstration, the PubChemData folder is used as the database directory
and the PubChemSignatures folder as the output directory. Shape distributions
are selected for use as the signatures (the pharmacophore signature is discussed
in Appendix C) and the default values are used. These values were chosen by
building histograms for a subset of the PubChem Compound database with the goal
of minimizing the number of empty or almost empty bins. Finally, one tells the
program to divide the work across X processes and to run Y processes per node.
Once again, the swarm utility is used to submit jobs to the cluster scheduler. Figure
3.3 shows the completed wizard for the example, using X = 12 and Y = 4. Clicking
the Finish button will submit the jobs to the scheduler.
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Figure 3.3: The interface for the Map program. A user points the program to the
molecular database and specifies the type of signature to generate as well as the
submission parameters (swarm parameters and the number of processes to spawn).
3.4.2 Cluster
The Cluster button can be clicked, from the SimSearcher window, to load the Cluster
wizard, which allows up to 3 levels of clustering to be performed. With the Cluster
wizard, one specifies the mapped (signature) directory, the output directory, the dis-
tribution test to use when assessing signature similarity (during K-means clustering),
the number of clusters to generate at each level, and the submission parameters.
For the demonstration, the PubChemSignatures (mapped) database is used and
the output is sent to the ClusteredDB directory. The χ2 distribution test is selected
to be used when comparing signatures. The number of clusters (the K in K-means
clustering) to generate at each level is then entered. To use 2 (or 1) level clustering,
one can specify 0 for the number of clusters at level 3 (and 2). Finally, one tells the
program to divide the work across X processes and run Y processes per node. Figure
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Figure 3.4: The interface for the Cluster program. A user points the program to the
signature database and specifies what similarity metric to use, how many clusters to
generate at each level, and what parameters to use for submission (swarm parameters
and the number of processes to spawn).
3.4 shows the completed wizard from the example, with X = 12 and Y = 4. Clicking
the Finish button will submit the clustering jobs to the scheduler.
3.4.3 Search
Searching the molecular database is the end goal of the process. The Search button
is used to load the Search wizard, which allows a search of a (clustered) signature
database. With the Search wizard, one specifies the signature database to be searched,
the target molecule (as an sdf file), the similarity test to use, and the number of similar
molecules to identify. The search is run on the local machine.
For the demonstration, the ClusteredDB is searched for the 10 molecules most
similar to the first compound in PubChem 3D (the compound with CID = 1). The
χ2 test is selected to be used to assess signature similarity. The completed wizard
for this step is shown in Figure 3.5. Upon clicking Finish, DockoMatic 2.1 will parse
the target molecule (CID 1) from the sdf file and generate a signature for it. It will
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Figure 3.5: The interface for the Search program. A user points the program to a
database of molecular signatures and specifies the target molecule and the number of
similar molecules to identify.
then use Algorithm 7 to locate the most similar signatures and output the ID and
similarity score associated with the 10 most similar signatures.
One can search the database with a set of target molecules by submitting a .txt
file as the Query Target. The text file should contain the path to each query target’s
sdf file, with one path per line.
For comparison, both PubChemSignatures and ClusteredDB were searched
with a single target molecule (CID = 1) for the 10 most similar molecules. The
PubChemSignatures search took a little more than 24 minutes to complete and
performed ≈ 51 million similarity calculations. In comparison, the ClusteredDB
search required a few seconds, performed ≈ 15, 000 similarity calculations, and found
the same 10 molecules.
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3.5 Conclusion
The development of additional signature types and corresponding similarity metrics
could increase SimSearcher’s utility. A pharmacophore-based signature and corre-
sponding similarity metric have been developed (see Appendix C) and are included
in DockoMatic 2.1, but pharmacophore clustering is not supported. Work remains to
be done to improve the speed and test the accuracy of the developed pharmacophore-
based similarity search.
Once a molecular database has been mapped to a signature database, the molec-
ular database can be deleted. If a researcher wishes to learn more about a molecule
(e.g., the one that was most similar to a target molecule), he or she can use the ID
to locate its information from the online database. This prevents researchers from
having to allocate hundreds of gigabytes of memory to store redundant molecular
information.
In summary, a model has been devised to allow quick similarity searches over local
molecular databases with any target molecule. The model consists of 3 steps: Map,
Cluster, and Search. In the Map step, signatures are generated for the database’s
molecules. In the Cluster step, N-level K-means clustering of the signature database
is performed to reduce the number of comparisons needed for a search. Each of these
steps needs to be performed once per database per signature type. In the Search
step, a recursive search algorithm is used to locate signatures similar to the target
molecule(s). The ID for the identified molecules are output, allowing the user to
search the original web database for additional information on the molecule. The
model has been implemented and integrated with DockoMatic 2.1.
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CHAPTER 4
CONCLUSIONS
4.1 Overview of Work
CAEPIDR was developed to explore the conformational ligand-binding space of the
α3β2 nAChR isoform and use the results to identify small molecule drugs that target
the receptor. A GA-based search procedure (GAMPMS) was used to heuristically
explore the ligand-binding domain of the α3β2 nAChR isoform using a 640,000 α-CTx
MII mutant library. The GAMPMS required only 9,344 docking calculations and
identified peptides with estimated binding affinities 70% higher than the original
α-CTx MII peptide.
In CAEPIDR’s repurposing step, the PubChem Compound database was searched
for molecules bearing a shape similar to the highest affinity α-CTx MII mutants. To
perform the search with small peptides, the database was downloaded and the shape
distribution based signatures were generated for each molecule. The signatures were
clustered using multilevel K-means clustering and searched with the peptide mutants.
The estimated binding affinities of the identified small molecules varied, but the top
molecule’s predicted affinity was 70% higher than that of the α-CTx MII peptide.
Some of the top identified small molecules, which are shown in Figure 3.1, are being
purchased from a vendor to provide additional validation for the approach.
CAEPIDR has been generalized and integrated with DockoMatic. DockoMatic
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2.1 contains an intuitive graphical interface for a peptide mutant screening workflow,
allowing a researcher to quickly create virtual peptide mutant libraries. The user
has the option to screen the peptide mutant library exhaustively or with an im-
plementation of GAMPMS. DockoMatic 2.1 also contains the SimSearcher module,
which facilitates the mapping, clustering, and searching of local molecular databases.
Searching a clustered database with SimSearcher requires a few seconds per target
molecule, and a list of target molecules can be submitted to facilitate larger searches.
As a result, DockoMatic is a powerful tool for researchers interested in the drug
repurposing model.
DockoMatic is an open source software tool and is available for download on
sourceforge.net.
4.2 Future Work
At this point, the first 3 steps of the workflow from Section 1.2 had been completed.
The 128 identified small molecules are promising candidates for repurposing to target
the α3β2-nAChR and treat Parkinson’s disease. However, much work remains to be
done before any of these drugs can be tested for treating Parkinson’s disease. For
example, Lipinski’s rule of 5, that can be used to remove candidates which have a
high chance of failing clinical trails, can be applied to filter the set of molecules. Once
a narrowed set is specified, members of that set must be purchased or synthesized
and tested in a lab setting to confirm the predictions of the computational methods.
However, these procedures are beyond the scope of this thesis; the 128 molecules
represent this thesis’ main contribution to the project.
The SimSearcher utility can be improved through additional experimentation
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to discover better default values for the shape distribution based signatures. Ad-
ditionally, pharmacophore features can be integrated into the signatures in order
to improve SimSearcher’s ability to identify molecules with similar bioactivity. A
pharmacophore-based metric has been implemented (see Appendix C) and has been
tested for effectiveness. Its performance (see Table A.1 from Appendix A) was
equivalent to that of the Chi-Square test. Unfortunately, this made it useless as
a complementary metric. Work remains to be done to modify the metric so that
it is capable of complimenting the shape distribution approach, which would give
researchers a better approximation for bioactivity similarity.
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APPENDIX A
DISTRIBUTION TESTS
The calcDistTest() function (below) was used to assess the similarity of shape-based
signatures. Since each signature was a fixed-size histogram, signatures were repre-
sented as an array of doubles. The calcDistTest() function was built to work with
one of four metrics, and the implementations of those metrics follow the code for
calcDistTest().
An experiment was performed to compare the performance of the shape distri-
bution approach, with each of the 4 distribution tests, to the results reported by
Bolton et al. on a 3-D conformer search of PubChem Compound [52]. To set up
the experiment, a set of 16 molecules was selected from the PubChem Compound
database. 8 of the molecules, set Pos, were ligands of prostaglandin synthase and
therefore had established similar bioactivity. These were the ligands reported on by
Bolton et al. While shape Tanimotos have an established threshold for similarity (.8
- .85), our approach did not. As a result, we also included a set of 8 molecules, Neg,
which were selected to be dissimilar to each other. Its use is explained below.
The pairwise similarity between all 16 molecules was assessed using each of the
4 implemented distribution tests. A threshold was used so that the tests could act
as classifiers. That is, if test(mola,molb) > THRESHOLD, then mola would be
considered similar to molb. The ideal classification for the 16 molecules is given by
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Equation A.1. The actual classification for all 5 tests (the 4 implemented tests as well
as the results reported by Bolton et al. for the Shape Tanimoto) are given in Table
A.1. In the experiments, the THRESHOLD was set so that there was no more than
1 false positive.
test(x, y) =

similar if x ∈ Pos& y ∈ Pos
not similar if x ∈ Neg& y ∈ Neg
(A.1)
Test True Positives False Positives
chiSquare 18 1
pdfL1 14 1
pdfL1 14 1
rootOfProduct 20 1
Bolton et al. 14 NA
Table A.1: Distribution Test results.
As can be seen, the shape distribution approach compared favorably to the tech-
niques used by PubChem 3D.
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public static double calcDistTest(double[] dist1, double[] dist2, String dtest) {
int x;
double sum = 0.0;
if (dist1.length != dist2.length){
sum = 0.0;
} else if (dtest.equals("chiSquare")) {
for (x = 0; x < dist1.length; x++){
sum += chiSquare(dist1[x], dist2[x]);
}
sum /= 2.0;
} else if (dtest.equals("pdfL1")) {
for (x = 0; x < dist1.length; x++){
sum += pdfL1(dist1[x], dist2[x]);
}
sum /= 2.0;
} else if (dtest.equals("pdfL2")) {
for (x = 0; x < dist1.length; x++){
sum += pdfL2(dist1[x], dist2[x]);
}
sum = Math.sqrt(sum);
} else if (dtest.equals("rootOfProduct")) {
for (x = 0; x < dist1.length; x++){
sum += rootOfProduct(dist1[x], dist2[x]);
}
sum = 1 - sum;
}
return sum;
}
Figure A.1: Function to compare distributions using the test arguments
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public static double chiSquare(double a, double b) {
double result = 0.0;
if ((a + b) != 0.0){
result = Math.pow(a - b,2) / (a + b);
}
return result;
}
public static double pdfL1(double a, double b) {
return Math.abs(a-b);
}
public static double pdfL2(double a, double b) {
return Math.pow(a - b,2);
}
public static double rootOfProduct(double a, double b) {
return Math.sqrt(a * b);
}
Figure A.2: Code for distribution tests
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APPENDIX B
K-MEANS CLUSTERING
The SimSearcher module uses N-level, K-means clustering to reduce the time required
for database searches. K-means clustering is an iterative clustering algorithm that
partitions a set of data points by placing K center points and adjusting their locations
until an optimal arrangement is found. An arrangement is considered optimal if the
sum of the distances between each data point and the cluster center closest to it is
minimized. However, our version of K-means clustering iterates for a set number of
cycles before stopping. At each iteration, a cluster center is moved to the average
coordinates of all the points that were in the cluster during the previous round.
B.1 In-Memory Clustering
When all the data points can be placed into main memory, algorithm 6 can be used to
perform N-level, K-means clustering by using Algorithm 8 as KMeans Cluster(DB).
B.2 Big Data Style
When all the data points cannot be placed into main memory, a different algorithm
needs to be used. In this case, algorithm 9 needs to be used. This algorithm assumes
a parallel computing infrastructure, and the parameter cores is used to specify the
number of processes to spawn during each iteration.
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Algorithm 8 In Memory KMeans Cluster(DB,K)
clusters← choose K random points as cluster centers
for i ∈ [0, X] do
for each point ∈ DB do
distance←MAX V ALUE
for each cluster ∈ clusters do
tmp← getDistanceBetween(cluster.center, point)
if tmp < distance then
closest← cluster
distance← tmp
end if
end for
closest.addPoint(point)
end for
for each cluster ∈ clusters do
distance←MAX V ALUE
for each point ∈ cluster.getPoints() do
run total+ = point.coordinates
end for
cluster.setCenter(run total/cluster.points.size)
end for
end for
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Algorithm 9 Big Data KMeans Cluster(DB, cores,K)
clusters← choose K random points as cluster centers
write clusters.getCenters() to centersf ile
partitions← partition(DB, cores)
for i ∈ [0, X) do
for each partition ∈ partitions do
spawn worker(partition, false) process
end for
wait for all workers to finish
if i ¡ X then
for each file ∈ worker totals file do
for j ∈ [1, K] do
running total[j]+ = running total cluster[j]
points in cluster[j]+ = count[j]
end for
end for
for j ∈ [1, K] do
cluster[j].setCenter(running total[j]/count[j])
end for
write clusters.getCenters() to centersf ile
end if
end for
for each partition ∈ partitions do
spawn worker(partition, true) process
end for
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Algorithm 10 worker(partition, final)
clusters← read from centersf ile
for file ∈ partition do
for each point ∈ file do
distance←MAX V ALUE
for each cluster ∈ clusters do
tmp← getDistanceBetween(cluster.center, point)
if tmp < distance then
closest← cluster
distance← tmp
end if
end for
if final then
closest.addPoint(point)
else
closest.add running total(point.coordinates)
closest.increment count()
end if
end for
if final then
append points to cluster file(clusters)
clusters.remove all points()
end if
end for
if 6 final then
write clusters.running totals and clusters.counts to worker’s totals file
end if
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APPENDIX C
PHARMACOPHORE-BASED SIMILARITY METRIC
Pharmacophore (feature) based similarity is another popular estimator of bioactivity
similarity. As such, a rotationally invariant function was developed to generate a
feature-based signature for a molecule, assuming a rigid structure.
A molecule’s data file contains information on atom locations, charge, and con-
nectivity, so simple graph traversal techniques can be used to determine the existence
of features within a molecule. For the algorithms in this section, we assume that a
function parseFeatures() exists that returns the features of the argument molecule.
Each feature has a type (e.g., ring, cation) and a location (set of (x,y,z) coordi-
nates), and the location of a composite entity (e.g., the molecule, a ring) is considered
to be the average location of its atoms. The feature-based signature generation
function is shown in Algorithm 11. The ID (its CID in the case of PubChem
Compound) and its features are parsed from a data file. Next, every feature is cast as
a typed vector originating at the molecule’s center. Finally, a 4-tuple (see Algorithm
12) is created for every pair of typed vectors in the molecule. The 4-tuple contains
the type of both of the typed vectors as well as their magnitude difference and the
angle between them.
A custom function was designed to map two feature-based signatures, s1, s2 to a
number sim ∈ [0, 1]. Before describing the function, we note that a signature is a
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Algorithm 11 map(molecule)
ID ← molecule.getID()
features← parseFeatures(molecule)
for each feature ∈ features do
feature.coordinates← feature.coordinates−molecule.getCenter()
end for
for each feati ∈ features do
for each featj ∈ features do
if i 6= j then
if NOT sampledList.contains((i, j)) then
FeaturePairs.add(generateFeaturePair(feati, featj))
sampledList.add((i, j), (j, i))
end if
end if
end for
end for
return ID, FeaturePairs
Algorithm 12 generateFeaturePair(vector1, vector2)
type1 ← vector1.getType()
type2 ← vector2.getType()
∆← L2Norm(vector1, vector2)
θ ← arccos vector1·vector2|vector1||vector2|
return < type1, type2,∆, θ >
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collection of FeaturePairs. Now, let µ and ρ be any positive integer. The metric is:
h(s1, s2) =
∑
∀x∈s1
f(x, s2)
|s2|µ (C.1)
where
f(x, s2) = MAX(g(x, y)) (C.2)
and where y ∈ s2. We also note that each 4-tuple in s2 is used at most once at
the in calculating the similarity between a 4-tuple:
g(x, y) =

0 if types don′tmatch
µρ−|θx−θy |
ρ
(1− |∆x −∆y|) otherwise
(C.3)
In other words, the function computes the similarity between two signatures by
summing the similarity between the most similar FeaturePairs in each signature. Fea-
turePair similarity is 0 if the feature types differ; otherwise, it is inversely proportional
to the difference in the angles and magnitudes.
The technique has the following shortcomings:
1. There is no defined average value for a collection of pharmacophore signatures,
so K-means clustering is unusable and queries require too many similarity
computations.
2. The signature generation assumes a rigid structure, which is inaccurate.
3. The method seems to classify small molecules in a manner similar to shape-based
similarity, so the methods do not complement each other well.
